|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19:a phase 1 clinical trial显示文摘No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functional disability in survivors require clinical evaluation.We performed a parallel assigned controlled,non-randomized,phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells(UC-MSCs)infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.The study enrolled 18 hospitalized patients with COVID-19(n=9 for each group).The treatment group received three cycles of intravenous infusion of UC-MSCs(3×107 cells per infusion)on days 0,3,and 6.Both groups received standard COVID-treatment regimens.Adverse events,duration of clinical symptoms,laboratory parameters,length of hospitalization,serial chest computed tomography(CT)images,the PaO2/FiO2 ratio,dynamics of cytokines,and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed.No serious UC-MSCs infusion-associated adverse events were observed.Two patients receiving UC-MSCs developed transient facial flushing and fever,and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion.Mechanical ventilation was required in one patient in the treatment group compared with four in the control group.All patients recovered and were discharged.Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated.Phase 2/3 randomized,controlled,double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19. | Fanping Meng Ruonan Xu Siyu Wang Zhe Xu Chao Zhang Yuanyuan Li Tao Yang Lei Shi Junliang Fu Tianjun Jiang Lei Huang Peng Zhao Xin Yuan Xing Fan Ji-Yuan Zhang Jinwen Song Dawei Zhang Yanmei Jiao Limin Liu Chunbao Zhou Markus Maeurer Alimuddin Zumla Ming Shi Fu-Sheng Wang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 16 |
| 2 | Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients:a randomized,double-blind,placebo-controlled phase 2 trial显示文摘Treatment of severe Coronavirus Disease 2019(COVID-19)is challenging.We performed a phase 2 trial to assess the efficacy andsafety of human umbilical cord-mesenchymal stem cells(UC-MScs)to treat severe coViD-19 patients with lung damage,based onour phase 1 data.In this randomized,double-blind,and placebo-controlled trial,we recruited 101 severe coVID-19 patients withlung damage.They were randomly assigned at a 2:1 ratio to receive either UC-MSCs(4×10^(7)cells per infusion)or placebo on day 0,3,and 6.The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28.Other imagingoutcomes,6-minute walk test(6-MWT),maximum vital capacity,diffusing capacity,and adverse events were recorded and analyzed.In all,100 COVID-19 patients were finally received either UC-MSCs in=65)or placebo(n=35).UC-MSCs administrationexerted numerical improvement in whole lung lesion volume from baseline to day 28 compared with the placebo(the mediandifference was-13.31%,95%Cl-29.14%,2.13%,P=0.08).UC-MSCs significanty reduced the proportions of solid componentlesion volume compared with the placebo(median difference:-15.45%;95%CI-30.82%,-0.39%;P=0.043).The 6-MWT showedan increased distance in patients treated with UC-MSCs(difference:27.00 m;95%CI 0.00,57.00;P=0.057).The incidence of adverseevents was similar in the two groups.These results suggest that UC-MSCs treatment is a safe and potentially effective therapeuticapproach for COVID-19 patients with lung damage.A phase 3 trial is required to evaluate effects on reducing mortality andpreventing long-term pulmonary disability. | Lei Shi Hai Huang Xuechun Lu Xiaoyan Yan Xiaojing Jiang Ruonan Xu Siyu Wang Chao Zhang Xin Yuan Zhe Xu Lei Huang Jun-Liang Fu Yuanyuan Li Yu Zhang Wei-Qi Yao Tianyi Liu Jinwen Song Liangliang Sun Fan Yang Xin Zhang Bo Zhang Ming Shi Fanping Meng Yanning Song Yongpei Yu Jiqiu Wen Qi Li Qing Mao Markus Maeurer Alimuddin Zumla Chen Yao Wei-Fen Xie Fu-Sheng Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 13 |
| 3 | Tuberculosis in prisons in sub-Saharan Africa – the need for improved health services, surveillance and control显示文摘 | Justin O’Grady Michael Hoelscher Rifat Atun Matthew Bates Peter Mwaba Nathan Kapata Giovanni Ferrara Markus Maeurer Alimuddin Zumla | 2010 | Tuberculosis2010，，2： | 1 |
| 4 | New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects显示文摘 | Alimuddin I Zumla Stephen H Gillespie Michael Hoelscher Patrick P J Philips Stewart T Cole Ibrahim Abubakar Timothy D McHugh Marco Schito Markus Maeurer Andrew J Nunn | 2014 | The Lancet Infectious Diseases2014，，4： | 1 |
| 5 | Diagnosing Helicobacter pylori In Vivo by Confocal Laser Endoscopy显示文摘 | Ralf Kiesslich Martin Goetz Juergen Burg Manfred Stolte Ekkehard Siegel Markus J. Maeurer Steven Thomas Dennis Strand Peter R. Galle Markus F. Neurath | 2005 | Gastroenterology2005，，7： | 1 |
| 6 | Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test显示文摘 | Stephen D Lawn Peter Mwaba Matthew Bates Amy Piatek Heather Alexander Ben J Marais Luis E Cuevas Timothy D McHugh Lynn Zijenah Nathan Kapata Ibrahim Abubakar Ruth McNerney Michael Hoelscher Ziad A Memish Giovanni Battista Migliori Peter Kim Markus Maeurer | 2013 | The Lancet Infectious Diseases2013，，4： | 1 |
| 7 | New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects显示文摘 | Alimuddin I Zumla Stephen H Gillespie Michael Hoelscher Patrick P J Philips Stewart T Cole Ibrahim Abubakar Timothy D McHugh Marco Schito Markus Maeurer Andrew J Nunn | 2014 | The Lancet Infectious Diseases2014，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员